Cleveland BioLabs Inc. (NASDAQ:CBLI) shares were down 4.6% on Monday . The stock traded as low as $2.06 and last traded at $2.08, with a volume of 50,446 shares traded. The stock had previously closed at $2.18.

The firm has a 50-day moving average of $2.50 and a 200-day moving average of $2.64. The firm’s market cap is $22.74 million.

Cleveland BioLabs (NASDAQ:CBLI) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.17) earnings per share for the quarter. Equities analysts expect that Cleveland BioLabs Inc. will post ($0.16) EPS for the current year.

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.